West Pharmaceutical Services INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
West Pharmaceutical Services, Inc. announces its 2026 Annual Meeting of Shareholders, detailing proposals for director elections, executive compensation, auditor ratification, and a shareholder proposal on board leadership.
NYSE
West Pharmaceutical Services, Inc. delivered robust financial performance in 2025 with over $3 billion in net sales and 8% adjusted-diluted EPS growth, while announcing CEO Eric Green's planned retirement in late 2026.
NYSE
West Pharmaceutical Services announces its annual shareholder meeting to be held virtually on May 6, 2025, with key voting items including the election of directors and executive compensation.
NYSE
West Pharmaceutical Services reported a slight decline in organic net sales for 2024 but saw a return to growth in Proprietary Products in the fourth quarter and remains optimistic about future growth drivers.
NYSE
West Pharmaceutical Services will hold its annual shareholder meeting on April 23, 2024, featuring proposals including the election of directors, executive compensation, and amendments to the company's articles of incorporation.
NYSE
DEF 14A: West Pharmaceutical Services Seeks Shareholder Approval for Governance Changes, Executive Pay
West Pharmaceutical Services is asking shareholders to vote on director elections, executive compensation, and amendments to the company's articles of incorporation at the upcoming annual meeting.